Collegium's OxyContin rival is first drug using Deterx anti-abuse tech launched in US

By Gareth Macdonald

- Last updated on GMT


Related tags Opioid Pharmaceutical drug Pharmacology

Collegium Pharmaceutical has launched the first product formulated using its Deterx anti-abuse technology in the US.

Xtampza ER is an oral extended-release formulation of the opioid oxycodone. It was approved by the US Food and Drug Administration (FDA) for the management of severe pain on April 26​.  

In Xtampza capsules active pharmaceutical ingredients (API) particles are enclosed in waxy, fatty-acid microspheres. These microspheres do not release the drug actives when subjected to physical and chemical manipulation.

The approach has advantages over antagonist and irritant-based anti-abuse technologies according to Collegium which said because the microspheres maintain the desired release profile products can be delivered as sprinkles directly or via feeding tubes.

Legal battle

Xtampza contains the same active ingredient as Purdue Pharma’s $3bn a year pain management medication, OxyContin OP.

The launch comes four months after the U.S. Court of Appeals for the Federal Circuit upheld​ an earlier ruling that invalidated four OxyContin OP patents owned by Purdue.

Collegium said Xtampza will be supported by 120-strong sales force that will market it to pain specialists and specialty representatives who will target hospitals and long-term care facilities.

Other candidate Collegium drugs being developed using the Deterx technology include versions of oxymorphone, hydrocodone, morphine and methylphenidate.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more